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Viruses are intracellular parasites that ensure their existence by converting host cells into viral particle producing entities or into
hiding places rendering the virus invisible to the host immune system. Some viruses may also survive by transforming the infected
cell into an immortal tumour cell. MicroRNAs are small non-coding transcripts that function as posttranscriptional regulators
of gene expression. Viruses encode miRNAs that regulate expression of both cellular and viral genes, and contribute to the
pathogenic properties of viruses. Hence, neutralizing the action of viral miRNAs expression by complementary single-stranded
oligonucleotides or so-called anti-miRNAs may represent a strategy to combat viral infections and viral-induced pathogenesis.
This review describes the miRNAs encoded by human viruses, and discusses the possible therapeutic applications of anti-miRNAs
against viral diseases.
Copyright © 2009 Ugo Moens. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Viruses are common habitants of the human population,
where they establish diﬀerent forms of infection, including
an acute, a chronic, or a persistent infection with production
of low levels of virions. Some viruses can exist in a true
latent state in which infectious particles are only produced
upon reactivation stimuli. Viruses that reside harmlessly in
their host can under certain conditions or in immunocom-
promised persons be responsible for malignant and non-
malignant diseases, which may even lead to the death of
the host. A causal role for human polyomaviruses (HPyV),
papillomaviruses (HPV), herpesviruses (HHV), hepatitis B
virus (HBV), hepatitis C virus (HCV), and human T-cell
lymphotropic virus type-I (HTLV-I) and cancer is accepted
(forrecentreviewssee[1–7]).Itisestimatedthatoncoviruses
areassociatedwith15%ofthehumancancers[8],whilenon-
malignant infections from human immunodeﬁciency virus
(HIV), HBV and HCV alone cause more than 3 million
deaths annually worldwide [9]. Other viral infections (HIV
no included) were responsible for the death of more than
6000 patients in Japan in 2006, ∼7000 individuals in the
USA in 2005, and 555 people in United Kingdom in 2006
according the statistics of the World Health Organization
[10]. Thus the pathogenic properties of viruses necessitate
the development of eﬃcient antiviral therapies.
Viruses attempt to create a favorable cellular environ-
ment allowing viral replication or survival by establishing
a lifelong latent infection through evading the immune
system of their hosts. Viruses can hide within a cell by
restricting their activity to a minimum so as not to conceal
their presence to the immune system and at the same time
they will also try to avoid apoptosis. For these purposes,
viruses have developed diﬀerent strategies, one of which
includes the posttranscriptional regulation of both cellular
and viral gene expressions through modulating the host’s
RNA-interference (RNAi) machinery. Viruses can suppress
the RNAi pathway by viral microRNA (vmiRNA) targeting
cellular or viral transcripts, or by viral proteins (e.g.,
human immunodeﬁciency virus Tat protein, inﬂuenza virus
NS1/NS2 protein, Ebola VP35 protein, and vaccinia virus
E3L protein) or viral RNA (Adenovirus VA transcripts)
that counteract the host’s RNAi machinery (for recent
reviews see [11–17]). This review summarizes the recent
ﬁndings on virus-encoded miRNAs and their described
functions and brieﬂy discusses the potential of antiviral
miRNA as a novel therapeutic strategy in combating virus
infections.2 Journal of Biomedicine and Biotechnology
2. MicroRNA (miRNA)
MiRNAs are noncoding small RNA molecules that act as
posttranscriptional regulators. They seem to be an inherent
part of the genomes of most living organisms as they have
been described in plants, unicellular and lower inverte-
brates, all vertebrates, and in viruses. Their exact functions
start to emerge and include control of cellular processes
such as diﬀerentiation, morphogenesis, organogenesis, and
metabolism [18–22]. MiRNAs are typically generated by
RNA polymerase II. The primary transcript (pri-miRNA)
is processed by the RNase III enzyme Drosha, in concert
with double-stranded (ds) RNA-binding protein DGCR8
into a ∼60 pre-miRNA hairpin. This nuclear pre-miRNA
is then transported into the cytoplasma by exportin 5/Ran-
GTP and cleaved by the cytoplasmic RNase III Dicer to
generate an imperfect ds RNA of 21–25 nucleotides. One
of the strands, the mature miRNA strand or guide strand,
is loaded in the RNA induced silencing complex (RISC),
and directs RISC to the target mRNA, where the complex
hybridizes to (partially) complementary sequences resulting
in cleavage or translational inhibition of the target mRNA.
The unincorporated strand, called the passenger strand, is
degraded. The seed region, which encompasses nucleotides
2 to 8 of the 5’ ends of miRNA, plays a pivotal role in
target selection by RISC-bound miRNA (for recent reviews
see [23–25]). In animals, mature miRNAs do not require
complete complementarity to their target mRNAs, enabling
them to bind to and prevent translation of several mRNAs.
Experimental evidence suggests that a single miRNA can
potentially target as many as 200 diﬀerent mRNAs [26–28].
A ss u c h ,m i R N A sh a v em e r g e da sp i v o t a lp o s t t r a n s c r i p t i o n a l
regulators of gene expression in multicellular eukaryotes and
aberrant expression can contribute to diseases ([28]a n d
references therein).
3. Silencingof miRNA by
Anti-miRNA Oligonucleotides
Anti-miRNA oligonucleotides (AMOs) are chemically mod-
iﬁed synthetic oligonucleotides that are complementary to
their target sequence and this will silence the action of
the target. AMOs are modiﬁed with the dual purpose
to stabilize them and to improve their aﬃnity for their
targets. One modiﬁcation is the 2’ sugar modiﬁcation
which implies a chemical modiﬁcation of the 2’-O of
the ribose residue (Figure 1(a)). The 2’-O -methyl AMOs
have a methyl group linked to the 2’-O of the ribose
residue, while the 2’-O - methoxyethyl AMOs contain a
methoxygroup. This modiﬁcation provides improved RNase
resistance and binding aﬃnity to RNA compared to unmod-
iﬁed antioligonucleotides. However, 2’-O -methoxyethyl
AMOs possess a higher aﬃnity and speciﬁcity to RNA than
their 2’-O -methyl AMOs. Other 2’ sugar modiﬁcations
that have been used include 2’-ﬂuor and locked nucleic
acid (LNA). In LNA-modiﬁed oligonucleotides, the 2’-O -
oxygen is bridged to the 4’-position via a methylene linker
to form a rigid bicycle, locked into a C3’-end (RNA)
sugar conformation (Figure 1(a)). LNAs give very strong
duplex formation with their target sequences and they
display excellent mismatch discrimination, hence avoiding
oﬀ-target eﬀects (for recent reviews see [28]a n d[ 29]).
LNA injections against miR-122, a cellular miRNA involved
in lipid metabolism, resulted in eﬃcient and long-lasting
decrease in plasma cholesterol in African green monkeys
without any evidence for toxicities [30]. A second type
of modiﬁcation is the phosphorothioate backbone which
reduces the aﬃnity to the target somewhat, but it confers
signiﬁcant stability to nuclease degradation (Figure 1(b)). A
third generation of antisense oligonucleotides are phospho-
diamidatemorpholinooligomers(PMO)inwhichtheribose
ring is replaced with a morpholine ring. Adding an arginine-
rich peptide (RXR)4 further increased the stability and tissue
retention of the PMO (reviewed in [31]). An additional
modiﬁcation can be made to improve the cellular uptake of
theAMO.Kr¨ utzfeldtetal.linkedacholesterolmoietytotheir
AMOs and referred to these anti-miRNAs as antagomirs.
Antagomirs should be >19 nucleotides in length to provide
highest eﬃciency in silencing target miRNA [32–34]. The
putative therapeutic potentials of antagomirs were recently
demonstrated in treatment of lipid metabolic disease in
animals [35]. An alternative class of AMOs is peptide nucleic
acids (PNA), which are synthetic oligonucleotides with N-
(2-aminoethyl)-glycine replacing the deoxyribose or ribose
backbone [36]. A study published in 2008 reported that PNA
can eﬃciently block the action of cellular miRNAs [37].
Finally, another approach in silencing miRNA is the use of
so-calledmicroRNAsponge,asyntheticmRNAthatcontains
multiple binding sites for a particular miRNA and that is
transcribed from a plasmid containing a strong promoter
(reviewed in [28]). In conclusion, diﬀerent classes of AMO
have been shown to be eﬃcient in silencing miRNA and may
be useful therapeutic tools (reviewed in [29, 32–34, 38]).
4.ViralmiRNAs EncodedbyHumanViruses
4.1. Human polyomaviruses. (HPyV) are nonenveloped
viruses with a circular ds DNA genome of approximately
5000 base-pairs. The members BK virus and JC virus were
ﬁrst isolated in 1971 from the urine of a renal transplant
patient with the initials B.K., and from the brain of a
Hodgkin’s lymphoma patient with initials J.C. who suﬀered
from progressive multifocal leukoencephalopathy (PML),
respectively. Human infections with the rhesus macaque
(Macaca mulatta) Simian vacuolating virus 40 (SV40) were
considered as accidental transmission of the virus from
monkeys to people living in close contact with these animals
or through vaccination with the contaminated poliovirus
vaccines. However, recent observations support the possibil-
ity that SV40 can spread in humans by horizontal infection
and even vertical transmission, suggesting that man may be
a natural host for this virus. The human polyomaviruses
seem to be implicated in tumours of the brain, bone,
colon,mesothelium,pancreas,stomach,urogenitaltract,and
lymphomas and leukaemias (reviewed in [39, 40]). In 2007,
two independent research groups reported the isolation
of two new human polyomaviruses from nasopharyngealJournal of Biomedicine and Biotechnology 3
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Figure 1: Common chemical modiﬁcations used for anti-miRNA oligonucleotides (AMO). (A) Modiﬁcations of the 2’-O residue in ribose.
(B) Modiﬁcation of the phosphate-ribose backbone. LNA = locked nucleic acid. See text for details.
samples and they are referred to as KIPyV WUPyV [41,
42]. This year a novel human polyomavirus, Merkel cell
polyomavirus (MCPyV), was identiﬁed that is associated
with Merkel cell carcinoma [43].
The HPyV genome can be divided into three functional
regions. The early region encodes the early proteins large
T-antigen (LT-ag) and small t-antigen (st-ag), while the
late region encodes the capsid proteins VP1-VP3 and the
regulatory protein agnoprotein. Both regions are separated
by the noncoding control region that encompasses the origin
of replication and the promoter/enhancer sequences for the
early and late genes (reviewed in [44]). The SV40 genome
e n c o d e sav i r a lm i R N A( v m i R N A )o fw h i c hb o t ha r m s
are complementary to the early viral mRNAs and reduces
expression of the early proteins (Figure 2(a); Table 1). Cells
infected with mutant SV40 lacking this miRNA or with wild-
type SV40 yielded comparable levels of infectious viruses,
but the latter were less sensitive to lysis by cytotoxic T cells
and produced less interferon-γ. Thus SV40-encoded miRNA
allows the virus to evade the immune system [45]. The SV40
miRNA is conserved in BKV and JCV and both miRNAs
generatedfromtheprecursorhairpinbindtothesametarget,
thatis,theearlytranscripts.TheBKVandJCVmiRNAsserve
the same role as SV40 miRNA, that is, downregulation of
early expression. JCV miRNA, miR-J1, was readily detected
in brain samples of PML patients, suggesting a biological
role of this miRNA [46]. The group of Sullivan has also
identiﬁed a MCPyV-encoded miRNA, miR-M1, which does
not share sequence identity with the known miRNAs of
the other polyomaviruses. MCPyV miR-M1 is located in
the early region (Figure 2(a)) and can downregulate early
gene expression. In accordance with SV40, this may allow
the virus to evade the immune system. However, MCPyV is
associated with Merkel cell carcinoma and the viral genome
is integrated in these tumours [43]. Blocking miR-M1 by,
for example, antagomirs will increase the expression of the
viraloncoproteinLT-antigenandassuchhavelittlebeneﬁcial
therapeutic eﬀect [47]. Expression of a corresponding or
other viral-encoded miRNA for the other HPyV WU and KI
is lacking so far.
4.2. Human Papillomaviruses. Human papillomaviruses
(HPV) are nonenveloped viruses with a circular dsDNA
genome of approximately 8000 base-pairs. These viruses are
associated with benign and malignant lesions of the skin and
the genital tract. More than 100 diﬀerent HPV genotypes
have been identiﬁed and based on their association with
benign warts or cancer, they are classiﬁed as low-risk and
high-risk variants, respectively [1].
One study with HPV type 31 failed to clone vmiRNA
fromvirus-infectedcells[58].However,thisdoesnotexclude
that other strains may encode vmiRNA. Moreover, the
expression of vmiRNA may be regulated in a temporal
and spatial manner, so that the experimental conditions
for capturing vmiRNA may be tricky. In addition, the high
mutation rate of HPV genome sequences may impede the
prediction of the presence of putative vmiRNA.
4.3. Human Adenovirus. Adenoviruses are naked dsDNA
viruses that can cause mild respiratory, gastrointestinal,
urogenital, and ocular disease. More than 50 serotypes have
been described in human. Although there is no proof for
a causative role in malignancies, adenoviruses can induce
cancerinanimalmodelsandhavebeenextensivelystudiedto
scrutinize viral mechanisms for cellular transformation [59].
Adenovirus encodes small noncoding RNAs, known as
virus-associated RNA or VAI and VAII RNA, which are
generated by RNA polymerase III. This noncoding RNA
plays an important role for viral replication and neutralizes
the antiviral action of interferon by blocking the dsRNA-
induced protein kinase (PKR), which phosphorylates and
thereby inactivates the eukaryotic translational initiation4 Journal of Biomedicine and Biotechnology
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Figure 2: Schematic representation of the genomes of diﬀerent human viruses and location of viral-encoded miRNAs. (A) The human
polyomavirus (HPyV) BK virus, JC virus, SV40, and Merkel Cell polyomavirus encode the viral miRNAs miR-B1, miR-J1, miR-S1, and miR-
M1, respectively [45–47]. (B) Herpes simplex virus-1 genome with detail of the LATlocus. The numbers refer to the approximate sequence
coordinates of the LAT locus. L= long, S= short, U= unique, TR= terminal repeat, and IR= internal repeat. The ﬁgure is modiﬁed after [48].
(C) Genomic map of HCMV with relative position of some of the genes. The open reading frames are depicted by thick arrows, while the
position of the viral miRNAs are indicated by narrow arrows. L= long, S= short, U= unique, TR= terminal repeat, and IR= internal repeat.
Modiﬁed after [49] and [50]. (D) Location of the miRNAs in the EBV genome. The latency genes are shown as grey boxes, while the miRNAs
are indicated by vertical lines. (E) Kaposi’s sarcoma-associated herpes virus (KSHV or HHV-8). Most KSHV miRNAs are clustered between
the kaposin(K12) gene and the v-FLIP(ORF71) gene, while two are located within the K12 open reading frame (ORF). Adapted from [51].
(F) The HIV-1 genome and location of the viral-encoded miRNAs. The ﬁgure is based on a compilation of the studies by [52–57].
factor 2 [60]. A recent study showed that a minor frac-
tion of VAI RNA is processed by Dicer into functional
RISC-associated ssRNA which can act as miRNA (Table 1).
Blocking of VAI-derived small RNA by 2’-O -methyl AMO
complementary to VAI decreased virion production [61–63].
In an attempt to identify potential targets for VAI-derived
miRNA, computational analysis was used. Putative targets
include genes encoding apoptosis-related protein NAPOR
and PKR-activating protein PACT. Therefore VAI RNA-
derived miRNA may help adenovirus to escape the actions
of the host defense mechanisms [64].
4.4. Human Herpesviruses. Herpesviruses are enveloped
dsDNA viruses with a genome size ranging between ∼130 to
∼250 kilobase-pairs. They are divided into three subfamilies
denoted α, β,a n dγ. Approximately 130 diﬀerent her-
pesviruses have been identiﬁed to date, including the human
α-herpesviruses herpes simplex virus 1 (HSV-1 or HHV-1),
herpes simplex virus 2 (HSV-2 or HHV-2), Varicella-zoster
virus(VZVorHHV-3),theβ-herpesvirusescytomegalovirus
(HCMV or HHV-5), HHV-6A, HHV-6B, and HHV-7, the
γ-herpesviruses Epstein-Barr virus (EBV or HHV-4), and
Kaposi’s sarcoma-associated virus (KSHV or HHV-8). All
human herpesviruses are able to establish latent infections
with only a small subset of viral genes expressed (reviewed
in [64]). As will be discussed in the next section, among the
viral transcripts that can be detected in latently infected cells
are viral-encoded miRNAs, which seem to be required to
maintain a latent state of infecton, but may also contribute
to the pathogenic properties of the virus.
4.4.1. HSV-1. Herpes simplex virus-1 (HSV-1 or human
herpes virus 1; HHV1) infects the majority of the human
population, but remains a latent cohabitant in most people.
Reactivation of the viruses usually results in cold sores,
but it can also cause a spectrum of diseases from sight-
threatening ocular infections in immunocompetent adults to
more severe infections in newborns and immunosuppressed
patients (reviewed in [89]).
An important gene in HSV latency is the LAT gene.
This gene encodes the latency-associated transcript (LAT),
which does not code for a protein. LAT seems to promote
cell survival of the infected cells [90]. Gupta and cowork-
ers proposed that the antiapoptotic activity of LAT was
achieved by an miRNA-entrapped in the LAT (miR-LAT),
which downregulates the expression of transforming growth
factor-β (TGF-β) and SMAD3. The latter is a mediator
of the signalling pathway induced by TGF-β, while TGF-
β can prevent cell proliferation and induce cell death [67].
However, a later study revealed that the described miR-LAT
wasnotviralencoded,butinfactacellularmiRNAexpressed
in SH-SY-5Y cells [67] and the report describing miR-LAT
was retracted [91]. Work by Umbach et al. could also not
conﬁrm the existence of this miRNA in HSV-1 infected SH-
SY-5Ycells[48].Later,itwasshownthattheHSV-1LATexon
encodes HSV-1 miR-LAT-ICP34.5, which can be detected in
HSV-1 infected cells [89]. Circa 120 base-pairs upstream in
this region, a sequence with 77% homology to the HSV-2
miRNAmiR-I(seefurther)ispresent,butnomaturemiRNA
was detected in HSV-1 infected cells. However, the existence
of this miRNA during HSV-1 latency in vivo remains to be
conﬁrmed [68].
Computational analysis predicted 24-miRNA candidates
in the HSV-1 genome, 8 of which were conserved in HSV-
2, suggesting they may be functional miRNAs [69]. The
authors conﬁrmed the expression of one mature miRNA,
designated miR-H1, in HSV-1 infected Vero cells, where it
was expressed late in productive replication. This miRNA is
encoded approximately 450 bp upstream of the transcription
start site of the LAT transcript, but a corresponding sequence
is not conserved in the HSV-2. The function of miR-H16 Journal of Biomedicine and Biotechnology
Table 1: MicroRNAs encoded by human viruses and their targets. See text for details.
Virus miRNA Target/function Reference
Human polyomaviruses
SV40 miR-S1 Downregulation early
expression; Immunomodulating [45]
BKV miR-B1 Downregulation early expression [46]
JCV miR-J1 Downregulation early expression [46]
MCPyV miR-M1 Downregulation early expression [47]
Human papillomavirus not predicted [65]
not detected [66]
Human adenovirus unnamed [61–63]
Human parvovirus not predicted [65]
HSV-1 (HHV1) miR-LAT
(within exon 1)
Prevents apoptosis by targeting
translation of the genes encoding
TGF-β1 and SMAD3
[67](retracted),[48, 68,
69],[70]
miR-LAT-
ICP34.5
miR-H1
Repression of the expression of
the viral protein ICP0, which
promotes viral replication
miR-H2 Downregulation of ICP34.5, a
key viral neurovirulence factor
miR-H3 Downregulation of ICP34.5, a
key viral neurovirulence factor
miR-H4
miR-H5 Downregulation of ICP4, a viral
transcriptional activator
miR-H6 Reduced expression of ICP34.5, a
key viral neurovirulence factor
HSV-2 (HHV2) miR-I
miR-II
miR-III
VZV (HHV3) not predicted [65, 71]
HCMV (HHV5) miR-UL23 Immunomodulating [12, 49, 65, 72–74]
miR-UL36-1
miR-UL54-1
miR-UL70-1
miR-UL22A-1
miR-UL112-1
Downregulates the expression of
CMV genes involved in its own
replication process, for example,
transactivators IE72 and IE86;
UL120/121; UL114MHC class
I-related chain B (MICB), a
cellular ligand for the activating
receptor NKG2D;
downregulation of IE-1
miR-UL148D-1
miR-US4-1
miR-US5-1
miR-US5-2
miR-US24Journal of Biomedicine and Biotechnology 7
Table 1: Continued.
Virus miRNA Target/function Reference
miR-US25-1
miR-US25-2
miR-US33-1
RNAβ2.7
Bnds components of the
mitochondrial respiratory chain
complex I and thus preventing
apoptosis
EBV (HHV4) miR-BART1-1
to -3 Inhibition LMP1 expression [24], [51, 75–79]
Inhibit EBV DNA polymerase
BALF5
miR-BART2 Inhibition LMP1 expression
miR-BART3
miR-BART4 Antiapoptotic by
downregulation of PUMA
miR-BART5
miR-BART6 Inhibition LMP1 expression
miR-BART7
miR-BART8
miR-BART9
miR-BART10
miR-BART11
miR-BART12
miR-BART13
miR-BART14 Inhibition LMP1 expression
miR-BART15 Inhibition LMP1 expression
miR-BART16
miR-BART17
miR-BART18
miR-BART19
miR-BART20 Downregulation chemokine
CXCL-11
miR-BHFR-1
miR-BHFR-2
miR-BHFR-3
KSHV (HHV-8) miR-K12-1 Downregulation of
thrombospondin 1 and BACH [51, 66, 75, 80–82]
miR-K12-2 Downregulation of
thrombospondin 1
miR-K12-3
miR-K12-4
miR-K12-5 Downregulation of
thrombospondin 1 and BACH
miR-K12-6
miR-K12-7
miR-K12-8
miR-K12-9
miR-K12-10a
miR-K12-10b Downregulation of
thrombospondin 1 and BACH-1;
miR-K12-11 Identical to miR-1558 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Virus miRNA Target/function Reference
miR-K12-12
Poxvirus vaccinia virus 3 predicted [65]
Poxvirus variola virus 1 predicted [65]
Hepatitis B virus [54]
Hepatitis C virus
Human immunodeﬁciency virus miR-H1
Type 1 (HIV-1) miR-TAR HDAC-1-mediated repression of
viral gene expression [83]
miR-TAR-5p [84]
miR-TAR-p
HAAmiRNA
Downregulation IL-15, IL-2
receptor γ chain, IRAK1, and
FMRP
[56]
VmiRNA#1-5
Proteins involved in, for
example, signal transduction,
protein synthesis, and
degradation, DNA methylation
[85]
miR-N367 HIV promoter interference [86]
HIV-2 miR-TAR2-5p [87]
miR-TAR2-3p
HTLV-I not detected [88]
Paramyxoviridae (measles virus) 1 predicted [65]
remains to be established and no cellular target mRNAs
were identiﬁed [69]. Umbach and coworkers detected in
addition to miR-H1 ﬁve novel viral miRNAs in trigeminal
ganglia of mice latently infected by HSV-1, as well as in
HSV-1-infected Vero cells. These miRNAs, that is, miR-H1
to miR-H6, are encompassed in the LAT locus (Figure 2(b)).
By quantitative RT-PCR, the authors were able to roughly
estimate the number of copies of each miRNA during
productive infection of Vero cells. MiR-H1 and miR-H6 were
expressed at ∼1200 and 300 copies, respectively, while the
other miR-Hs were present at less than 40 copies per infected
cell. In latently infected trigeminal ganglia, much higher
levels were monitored with 63000 copies of miR-H2, 8000
copiesofmiR-H3,800000copiesofmiR-H4,80000copiesof
miR-H5, and 40000 copies of miR-H6. The large diﬀerence
in numbers of miRNA transcripts in latently infected cells
compared to cells with productive HSV-1 infection indicates
that miR-Hs play an important role in establishing latent
HSV-1 infection. Indeed, miR-H2 expression diminished the
protein levels of ICP0, a viral transcriptional activator that
promotes viral replication, while miR-H6 inhibits expression
of ICP4, which is required for expression of most HSV-1
genes during reproductive infection [48].
4.4.2. HSV-2. HSV-2 typically infects the genital region and
establishesalifelonglatentinfection.Theprevalenceoflatent
HSV-2 infection varies between 10–60%. Reactivation can
cause oro-facial and genital herpes, but HSV-2 infection can
also cause encephalitis and neonatal herpes, and forms a risk
factor for HIV acquisition [89]. The only detectable viral
transcriptduringHSV-2latencyistheLAT,butthemolecular
function of this transcript remains largely unknown [92].
HSV-2 LAT exon encodes an miRNA, referred to as miR-
I, which is expressed during latent, as well as during acute
infection. Remarkably, several promoters regulate miR-I
expression in diﬀerent stages of the viral life cycle. This
HSV-2 miRNA eﬃciently diminishes the expression of
the viral neurovirulence factor ICP34.5, a multifunctional
protein required for viral replication in neuronal cells in
vivo, and with intrinsic neurovirulent properties [93]. Thus,
miR-I may aﬀect the outcome of infection (latent versus
productive) by modulating the protein levels of ICP34.5.
Whether miR-I has other targets remains to be investigated,
but an miR-I analogue is also expressed by HSV-1, indicating
the importance of this miRNA for these viruses [68]. Tang
and colleagues identiﬁed two new HSV-2 miRNAs, miR-
II, which includes miR-II-5p and miR-II-3p, and miR-III,
both encoded by exon 2 of LAT. The expression of miR-I, -
II, and –III increased during infection of cells, but miR-III
displayedslowerkineticsthanthetwoothermiRNAs.Similar
to miR-I, miR-II silences the expression of ICP34.5,whileJournal of Biomedicine and Biotechnology 9
miR-III functionally resembles HSV-I miR-H2 in that it can
downregulate the expression of ICP0 [70].
4.4.3. Varicella-Zoster Virus (VZV). VZV is a common virus
that causes chickenpox or varicella during primary infection.
The virus establishes a latent infection, but reactivation leads
to herpes zoster, commonly referred to as shingles. Acute
VZV reactivation may lead to post-herpetic neuralgia [94].
No putative miRNAs could be predicted in the VZV genome
[65, 71], but experimental studies to unambiguously proof
the existence of VZV miRNA are lacking.
4.4.4. Human Cytomegalovirus (HCMV). HCMV causes
mild or subclinical diseases in immunocompetent adults,
but can lead to life-threatening complications in immuno-
compromised patients such as organ transplant recipients
and AIDS patients. In addition, HCMV is one of the
leading viral causes of birth defects and has been implicated
in the acceleration of long-term vascular diseases such
as atherosclerosis. Depending on the tissue type and the
host’s immune state, HCMV can establish acute, persistent,
or latent infections characterized by diﬀerent viral gene
expression [95, 96]. Because other herpesviruses encode
miRNAs, it was assumed that HCMV may encode miRNAs
whichcouldbeinvolvedindeterminingthetypeofinfection.
To date, 15 HCMV vmiRNAs, scattered throughout the viral
genome, have been identiﬁed (see Table 1 and Figure 2(c)).
Three viral miRNAs, designated as UL23-5p, miR-UL23-3p,
and miR-US24, were identiﬁed that are expressed during
productiveHCMVinfectionofpermissivecells(humanfore-
skin ﬁbroblasts, astrocytoma U373MG cells, retinal pigment
epithelial cells, and human microvascular endothelial cells).
Their putative cellular target genes include genes encoding
transcriptionfactors(e.g.,HNF3andTGIF2),receptors(e.g.,
IL-18 receptor 1 precursor; CD206), proteins implicated in
T-cell activation (AHNAK1), in signal transduction (e.g.,
RAB2L), and in biosynthesis of leukotrienes that sustain
inﬂammatory reactions (coactosin-like protein). Whether
thesegenesrepresentbonaﬁdetargetsaswellasthebiological
relevance of HCMV miRNA-mediated silencing of these
genes remains elusive [49].
HCMV usually establishes a lifelong persistent or latent
state in healthy individuals by ensuring that infected cells
avoid immune recognition. The HCMV-encoded miRNA
miR-UL112-1seemstoplayacentralroleinhelpingthevirus
to hide from the host’s immune system. This viral miRNA
targets mRNA for MHC class I-related chain B (MICB), and
to a lesser extend MICA. These proteins are cellular ligands
for the activating receptor NKG2D, which is expressed on
some natural killer (NK) cells, γ/δ T cells, and CD8+ T
cells. During cellular stress (such as viral infection) MICB is
induced, thus activating NK-cells and T cells that can lead to
the killing of infected cells. Cells infected with mutant virus
lacking this miRNA were more susceptible to being killed in
an NKG2D-dependent manner by NK cells [72].
The miR-UL112-1 also represses the expression of
HCMV genes involved in its own replication process, in part
by targeting mRNA encoding immediate early proteins. One
of them is the viral transactivator protein called immediate
early 72 (IE72) that regulates the transcription of viral genes
requiredforacutereplication[50].IE72playsapivotalrolein
controlling latency and reactivation. miR-UL-112-1 can thus
restrict reactivation of the virus through negative regulation
ofIE72expression[50,95].Twoseparatestudiesshowedthat
miR-UL112-1 also inhibited expression of the immediate
early protein IE1. Murphy et al. detected increased IE1 levels
in cells infected with either a virus lacking miR-UL112-
1 or with mutations in the seed sequence of the ie1 gene
compared to cells infected with wild-type HCMV [73]. Grey
and coworkers demonstrated that addition of miR-UL112-
1 RNA prior to infection reduced IE1 protein levels and
blocked viral replication [74]. IE1 is a crucial protein to
ascertain lytic replication of HCMV, thus downregulation of
IE1 may help the virus to establish latency. This strategy may
be a common feature for herpesviruses because immediate-
early genes may be putative targets for HSV-1 miR-LAT,
EBV miR-BART15 and miR-BHRF1-3, and KSHV miR-
K12-6-3p [73]. Yet another target for miR-UL112-1 is the
viral protein UL114, a homologue of the mammalian DNA
repair enzyme uracyl-DNA glycosylase. UL114 is required
for eﬃcient viral DNA replication. Hence, miR-UL112-1-
mediated downregulation of UL114 may prevent viral DNA
replication and favor a latent infection state [65]. Taken
together, the actions of miR-UL112-1 seem to be associated
with latent viral infection, a state which allows the virus to
hide from the immune system. Ablating expression of this
viral-encoded miRNAs by AMOs may therefore force the
virus into a lytic cycle and provide the immune system the
opportunity to get ride of the viral infection.
4.4.5. EBV. Epstein-Barr virus (EBV) or human herpses-
virus-4 (HHV-4) is a γ-herpesvirus that establishes a lifelong
latent infection in B-lymphocytes in more than 90% of
the human population. EBV is associated with infectious
mononucleosis and has been implicated in the pathogenesis
of several malignancies including Burkitt’s and Hodgkin’s
lymphomas, posttransplant and T-cell lymphomas, X-linked
lymphoproliferative syndrome, nasopharyngeal, and gastric
carcinomas [97]. Latently EBV-infected cells are classiﬁed
in stage I, II, or III, each of them characterized by distinct
EBV gene expression [98]. Among the latency stage-speciﬁc
EBV transcripts are miRNAs. More than 20 diﬀerent EBV
miRNAs have been identiﬁed that are transcribed during
latent infection (Table 1;[ 25, 51, 75–79]). The EBV miRNAs
are organized in two major clusters within the EBV genome
(Figure 2(d)). One cluster resides in the BART (abbreviation
for BamHI-A rightward transcripts) region. The BART
region gives rise to multispliced transcripts and is highly
expressed in EBV-positive cancers and in epithelial tissues,
while there is low BART expression in B lymphocytes. The
exact function of BART mRNAs remains obscure [76]. The
intronic region of BART also encodes the miRNAs miR-
BART1 to miR-BART20. The second region that encodes
multiple miRNAs is the untranslated region of the gene
encoding BHRF1 (BamHI fragment H rightward open
reading frame 1), a viral Bcl-2 homologue that prevents10 Journal of Biomedicine and Biotechnology
apoptosis. BHRF1 encompasses the miRNAs miR-BHRF-1-
1 to miR-BHRF-1-3 [51, 75].
The expressions of EBV-encoded miRNAs in clinical
samples and computational analysis to predict putative
targets were applied to unravel the biological functions of
EBVmiRNAs.TheseapproachesshowedthatthemiR-BARTs
are abundantly expressed in latently infected epithelial cells,
nasopharyngeal carcinomas, EBV-associated gastric carci-
nomacelllines andtissues,Burkitt’s lymphomaslatencytype
I, EBV positive primary eﬀusion lymphomas, and diﬀuse
large B-cell lymphomas, but at a signiﬁcantly lower level in
B cells. This corresponds well with the expression pattern
of BART multispliced transcripts (see above). Higher levels
of BHRF1-3 were measured in latency type III Burkitt’s
lymphomas and in diﬀuse large B-cell lymphomas [66, 79,
98–100]. Another study demonstrated that induction of
EBV replication in latency I-infected cells was associated
with increased expression of miR-BHRF1-1, -2, and -3, but
expression levels of miR-BART-1 and -2 did not change.
On the other hand, induction of EBV replication in latency
III-infected cells did hardly change the expression levels
of BHRF1-1, -2, and -3 [98]. These observations suggest
that EBV miRNAs may be implicated in the oncogenic
properties of the virus, but also in regulating its replication.
Moreover, a precise knowledge of the latency state of EBV
and the expression pattern of viral miRNAs may improve the
successful treatment of EBV infection with AMOs.
The function of most EBV vmiRNA remains poorly
understood, but some targets of EBV miRNAs have been
recently identiﬁed. Several mi-BARTs prevent expression
of viral latent infection membrane protein 1 (LMP1)
protein (see Table 1). LMP1 functions as a constitutively
active tumour necrosis receptor [101], and can activate
several signalling pathways including NFκB, AP1, JAK/STAT,
MEK/ERK, and PKC. LMP1 can also interact with p53
and aﬀects cyclins, cyclin-dependent protein kinases (CDK),
and the CDK inhibitors p16 and p27 (reviewed in [102]).
Furthermore,LMP1isexpressedinalltheEBVrelatedmalig-
nancies and promotes cellular transformation. Its oncogenic
property makes LMP1 an attractive target for EBV therapy.
Interestingly, overexpression of LMP1 results in growth-
inhibitory and sensitization to apoptosis induced by stress or
chemotherapeutic agents ([76] and references therein). Thus
AMO-mediated neutralization of mi-BARTs may lead to ele-
vated LMP1 protein levels and render EBV-positive tumour
cells more susceptible to chemotherapy. The viral miRNA
miR-BART2 can inhibit expression of viral DNA polymerase
BALF5 and may thus interfere with viral replication and
prevent lytic infection [51, 77]. Silencing miR-BART2 could
thus allow the virus the complete its life cycle and produce
new infectious virus particles, which then could oﬀer the
immunesystemtheopportunitytodetectandeliminateEBV.
Using computational prediction programs such as miRanda
and RNAhybrid (reviewed in [103]) allowed Choy and
coworkers to envisage the cellular protein p53 up-regulator
of apoptosis (PUMA) as a target for miR-BART5 [78]. The
authors demonstrated that PUMA levels were decreased in
cells expressing miR-BART5 compared to cells lacking miR-
BART5. In accordance, when miR-BART5 was speciﬁcally
inhibited with an anti-miR-BART5 oligonucleotide, PUMA
protein levels decreased and apoptosis was triggered. Thus,
EBV may promote survival of infected epithelial cells by
modulating the expression of an apoptotic protein through
an miRNA-mediated mechanism. This ﬁnding may have
important implications in the development of anti-EBV
agents such as AMOs directed against miR-BART5.
Fewer studies have been directed to determine the targets
of miR-BHRF1s. miR-BHRF1-2 is involved in the cleavage of
BHRF1 RNA in the cytoplasm, but the biological relevance
remains to be determined [98]. In another study, Xia et al.
observed that high levels of miR-BHRF1-3 were correlated
with low levels CXCL-11, a potent interferon-inducible T-
cell attracting chemokine. MiRNA-mediated suppression of
CXCL-11 may serve as an immunomodulating mechanism
allowing the virus to survive in the host [79]. On the
other hand, enhancing CXCL-11 expression in EBV-positive
tumours by AMOs against miR-BHRF1-3 may increase
susceptibility of the tumour cells to the immune system. In
agreement with this, two recent studies reported antitumour
activity for CXCL-11 in animal models [104, 105].
4.4.6. Kaposi’s Sarcoma Virus (KSHV or Human Herpes
Virus Type 8; HHV-8). Kaposi’s sarcoma-associated virus,
so named because it was detected in Kaposi’s sarcoma,
belongs to the γ-herpesviruses and is also known as human
herpesvirus-8 or HHV-8. HHV-8 is associated with Kaposi’s
sarcoma, as well as with two rare forms of B-cell malig-
nancy: primary eﬀusion lymphoma (PEL) and the plasma
cell variant of multicentric Castleman’s disease. Like other
herpesviruses, KSHV can establish a lifelong latent infection
characterized by a limited viral gene expression [106].
A total of 17 KSHV miRNAs encoded by 12 distinct
miRNA genes have been reported and their sequences
are highly conserved between diﬀerent KSHV genomes
in PEL cell lines and in clinical samples. However, some
polymorphism was observed, particularly in miR-K12-5 and
miR-K12-9 [80, 107, 108]. The entire KSHV miRNA cluster
resides within an approximately 4 kilobase-pairs region
between open reading frames ORF K12 (kaposin) and ORF
71 (Figure 2(e)).
To elucidate the functions of the KSHV miRNAs,
transcriptome analysis was performed from cells stably
expressing the miR-K12 cluster. Among the diﬀerentially
expressed genes were genes encoding proteins implicated
in proliferation, immune modulation, angiogenesis, and
apoptosis. The gene encoding thrombospondin-1 was tar-
geted by all ten KSHV miRNAs, but especially by miR-
K12-1, miR-K12-3-3p, miR-K12-6-3p, and miR-K12-11.
Thrombospondin-1 possesses antiproliferative and anti-
angiogenic properties. Other transcripts that were reduced
corresponded to the genes for osteopontin, S100 calcium
binding protein, plasticity related gene 1 product, and
integral membrane protein 2A [80, 81]. The mRNA for the
Bcl-2 interacting protein BCLAF1 was identiﬁed as a target
for miR-K12-5. Additional inhibition of BCLAF1 expression
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exact biological relevance is not yet understood, but siRNA-
mediated depletion of BCLAF1 enhanced the frequency of
spontaneous lytic reactivation of KSHV. MiRNA-mediated
reduction of BCLAF1 expression would prevent permanent
latencyofthevirus,atypeofinfectionthatrepresentsadead-
end pathway of viral spreading [108, 109].
A KSHV miRNA that has gained special interest is miR-
K12-11 because its seed sequence, known to be critically
important for mRNA target recognition is 100% conserved
with the cellular miR-155, suggesting that these miRNAs
may regulate common targets. The exact role of miR-155
remains unclear, but a number of B-cell lymphomas and
solid organ tumors overexpress miR-155, while miR-155
transgenic mice develop B lymphomas [110, 111]. Work
by the groups of Skalsky and Cullen conﬁrmed that miR-
K12-11 indeed is an orthologue of miR-155, and that they
target common transcripts [81, 82]. Comparing the gene
expression proﬁles in cells stably expressing either miR-155
or miR-K12-11 revealed that they regulate an analogous set
ofmRNAs.Theproductsofthesetranscriptsincludeproteins
involved in B-cell function (e.g., Src-like adaptor or SLA),
innate immunity (e.g., IκB kinase and phosphoinositide-
3-kinase), apoptosis (XIAP associated factor-1; LDOC1),
cell cycle regulation (e.g., FOS), and gene expression (e.g.,
FOS and BACH1). BACH-1 (Btb and CNC homolog 1)
is a bZip protein that can repress transcription through
heterodimerization with the small Maf proteins [112], while
c-Fos can heterodimerize with the JUN proteins to form the
AP-1 complex. AP-1 is a multifunctional protein involved in
cellular proliferation, transformation, and apoptosis [113].
For a complete list of miR-155/miR-K12-11 regulated genes,
the reader is referred to the work of Skalsky et al., and
of Gottwein et al. [81, 82]. Treatment of latently-infected
KSHV with an antagomir against miR-K12-11 enhanced Fos
protein levels about 2.5-fold compared to untreated cells
[81]. Computational analyses further revealed seed sequence
homology between the viral miRNAs KSHV miR-K12-6-5p,
EBV-BART5, and HCMV UL70-5p with human miRNAs
miR-15a plus 16, miR-18a/b, and miR-340, respectively [82].
Both miR-15a and miR-16 are believed to possess tumour
suppressor activity and to induce apoptosis by silencing Bcl2
expression, while miR-18 was demonstrated to be oncogenic
[52, 114]. KSHV-encoded miRNAs seem to be crucial both
in survival of the virus in its host, but also to play a
causal role in viral-associated pathologies. AMO-mediated
silencing of KSHV-encoded miRNAs may thus be a strategy
to counteract viral infection, but may also undesirably target
cellular miRNAs with identical seed sequences as the viral
miRNAs.
4.5. Poxvirus. Poxviruses are dsDNA viruses that replicate
in the cytoplasm and have as such no access to the nuclear
proteins involved in the biogenesis of miRNA. Nevertheless,
miRNA precursor sequences have been predicted in the
genomes of the human poxviruses vaccinia virus and variola
virus, but their existence has not been validated [25, 65].
Whether the other human poxvirus, molluscum contagio-
sum virus, encodes miRNA remains to be established.
4.6. Hepatitis B Virus. Hepatitis B Virus (HBV), an
enveloped virus with a circular partial dsDNA genome,
persistently infects more than 300 million people worldwide.
HBV can cause a spectrum of liver diseases ranging from
mild liver dysfunctions to chronic hepatitis, cirrhosis, and
hepatocellular carcinoma [53]. This makes eﬃcient anti-
HBV therapy highly vital. AMO-based vmiRNA silencing
is probably no option since no miRNAs could be detected
by computational analysis [65], and expression of HBV
miRNAs has not been reported so far. One study identiﬁed
a putative HBV-encoded miRNA, but in vivo expression of
this HBV miRNA was not tested. Computational screening
for complementary sequences in the 3’ untranslated regions
ofcellularmRNAtothisHBVmiRNAdidnotrevealputative
target transcripts [54]. It therefore seems unlike that this is a
bona ﬁde viral miRNA.
4.7. Human Immunodeﬁciency Virus (HIV). HIV is the
causative agent of acquired immune deﬁciency syndrome
(AIDS), and it is estimated that >30 million people world-
wide are infected with this virus. Two species, HIV-1 and
HIV-2, infect humans (for a recent review see [55]).
HIV utilizes reverse transcriptase to convert its ssRNA
genome into a dsDNA provirus. During this process, the
5’ and 3’ ends of the viral RNA genome are converted
into long terminal repeats (LTRs). The LTRs play a pivotal
regulatory role in establishing, maintaining, and overriding
the latent state of the virus [115]. The central domain of
the LTR is referred to the R region, which encompasses
the (transactivation-response region) TAR. TAR binds the
viral protein Tat, a transactivator that plays an important
role in the transcriptional activation of the provirus genome
(reviewed in [116]). The TAR encodes proven and putative
miRNAs (Figure 2(f)). Klase and coworkers described an
miRNA encoded by the HIV-1 TAR element. This miRNA
causes HDAC-1 to associate with the viral LTR, resulting
in diminished viral gene expression. This suggests a role
for HIV-1 miRNA in maintaining viral latency [83]. In
another report, Ouellet and colleagues demonstrated the
expression of two TAR element-derived miRNAs by North-
ern blotting, primer extension, and RNase protection assay.
The miRNA derived from the left arm of the TAR stem
has been named miR-TAR-5p, while the miRNA originating
from the right arm was designated miR-TAR-3p. The latter
appears to preferentially accumulate in HIV-positive cells
[84]. The biological role of these miRNAs remains to be
elucidated, but they may contribute to modulating viral
and/or cellular gene expression, with a potential impact
on viral replication and/or host antiviral defense eﬃciency.
The miR-TAR-5p described by Ouellet overlaps with the
vmiRNA no. 1, while miR-TAR-3p partially overlaps with
vmiRNA no. 5 described by Bennasser and coworkers [85].
Theypredictedbycomputer-directedanalyses5pre-miRNAs
in the HIV-1 genome, which in principle could yield 10
mature miRNAs. Their expression has not been validated,
nor has their biological role been addressed, but deduction
of potential target transcripts resulted in the indentiﬁcation
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proteins involved in protein synthesis and degradation,
growth factors, and DNA methylation [85]. TAR DNA of
the long terminal repeat of HIV-1 encompasses an antisense
RNA (HIVaINR), which encodes HIV proteins, but that
can also form a duplex with the 5’ end of all sense HIV
mRNA, enabling the virus to control the expression of
i t sg e n e[ 117]. HIVaINR can potentially code for several
miRNAs, referred to as HAAmiRNAs. Putative targets for
these miRNAs are the mRNAs for interleukin (IL)-15, IL-2
receptor γ chain, human fragile X mental retardation protein
(FMRP), and IL-1 receptor-associated kinase 1 (IRAK1).
IL-15 is important in the regulation of T-cell maturation,
development and survival of natural killer cells, and survival
of long-lived memory T cells, while the IL-2 receptor γ chain
is a common component of the receptors for IL-2, -4, -7,
-9, -15, and -21. Aberant expression of this receptor leads
to severe T-cell and NK-cell deﬁciencies. IRAK1 is a critical
signalling mediator of innate immunity. Downregulation the
expression of IL-15, IL-2 receptor γ chain, and IRAK1 by
HIV miRNA would impair the immune system and favor
survival of the virus in the host. FMRP is an RNA-binding
protein that is implicated in protein synthesis and miRNA
processing. Thus HIV could use HAAmiRNA to deregulate
thehostmiRNAmechanismtodisposethevirusbydepleting
FMRP ([56] and references therein.) Although the existence
of these HAAmiRNAs has not been proven, it is tempting to
speculatethat,inaccordancewithotherviruses,HIVencodes
miRNAs allowing HIV to survive in the host. A recent study
examined the possibility of HIV-2 TAR to encode miRNAs.
Two putative miRNAs, miR-TAR2-5p and miR-TAR-3p were
identiﬁed, but their expression awaits validation [87].
Besides TAR, other regions of the HIV genome have been
shown to contain miRNA sequences. The nef gene of HIV-
1 is located at the 3’ end of the viral genome and is highly
expressed during the early stages of virus replication. Nef
is a multifunctional accessory protein that is important for
viralreplication,butthatalsoplaysakeyroleinpathogenesis
as Nef can downmodulate CD4, CD28, and the class I
major histocompatibility complex [86]. HIV-1 encodes a
nef-derived miRNA referred to as miR-N367 (Figure 2(f)).
Unlike classical miRNA, this miRNA does not aﬀect gene
expression at the post-transcription level, but rather at
the transcription level by promoter interference. MiR-N367
suppresses HIV-1 promoter activity via a negative responsive
element in the 5’-long terminal region and via Nef sequences
in the 3’ untranslated region [57, 118]. Future studies are
required to elucidate the precise mechanism by which miR-
N3667 represses HIV-1 promoter activity. Downregulation
of Nef expression may suppress HIV-1 replication and allow
persistently low pathogenic or latent viral infection [57]. As
the nef gene is conserved in HIV-2, HIV-2 may also apply a
similar mechanism to maintain a low proﬁle in the host.
The identity and action of HIV miRNAs remains to be
scrutinized before AMOs-based therapy can be considered
as anti-HIV drugs. However, computational alignment of
the potential HIV-1 miRNAs with speciﬁc human T-cell
mRNAs identiﬁed potential cellular targets including genes
encoding CD4, CD28 and interleukin-2, IL-3, and IL-12
[119]. Viral miRNA-caused inhibition of the expression
of these proteins seems advantageous for the virus, and
therefore counteracting vmiRNA by AMO may help the host
to clear HIV infection.
4.8. Human T-cell leukaemia virus type 1 (HTLV-I). HTLV-
I persistently infects 10–20 million humans worldwide and
is the etiological agent for adult T-cell leukaemia [5]. One
study reported that T cells persistently infected with HTLV-1
didnotexpressviralmicroRNAs[88],butmeticulousstudies
should be performed to rule out the existence of HTLV-I
miRNA.
4.9. RNA Viruses. Pfeﬀer et al. tried to identify miRNA
in the genomes of human RNA viruses like Marburg and
Ebola virus (Filoviridae), measles virus (Paramyxoviridae),
poliovirus (Picornaviridae), yellow fever virus and hepatitis
C virus (HCV; Flaviviridae), and Sindbis virus (Togaviridae).
NoneoftheseviralgenomesseemtocontainputativemiRNA
sequences, except for measles virus and yellow fever virus,
which each possesses a single putative miRNA. However,
the miRNA in yellow fever virus could not be validated,
while the existence of miRNA in measles virus was not tested
[25, 65]. Intriguingly, the liver-speciﬁc miR-122 facilitates
the replication of the oncovirus HCV, but the mechanism for
thisfunctionofmiR-122inHCVreplicationisstillunknown
[120, 121].
5. Conclusions
Numerous human diseases are caused by viral infections, but
the intimate relation with the host makes the development
of antiviral drugs diﬃcult. Vaccination has been proven to be
verysuccesfultocombatsomeviralinfections,butmutations
and diversity of virus strains has hampered the development
ofeﬃcientvaccinesagainstotherviruses.Newantiviraltreat-
ments are based on drugs that inhibit speciﬁc viral activities
such as viral proteases or polymerases (for recent reviews see
[122, 123]).Viral-encoded miRNA that may be implicated in
the viral life cycle and the pathogenic properties of the virus
oﬀers a novel attractive target for antiviral therapy. Silencing
the action of viral miRNAs may enable the host cell or the
immune system to gain control over the virus and even to
eliminate the virus. The idea of targeting viral transcripts
is not new, and RNA interference has been demonstrated
to eﬃciently mediate inhibition of replication of human
pathogenic viruses such as HIV-1, HCV, dengue virus, severe
acute respiratory syndrome (SARS) coronavirus, poliovirus,
human rhinovirus, inﬂuenza A virus, hepatitis D virus, HBV,
HSV-1, HPV, JCV, EBV, and CMV in cell culture (reviewed
in [12]). Besides recent studies have proven the potential
of this RNA interference as antiviral therapy in animal
models [124, 125], and even in clinical trials such as Alnylam
against respiratory syncytial virus and NUC B1000 against
HBV (reviewed in [126, 127]). However, anti-HIV RNA
interference studies revealed that escape virus variants could
appear which could evade the inhibitory action of siRNA
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The use of AMO to neutralize viral miRNA adds a
new twist to RNA interference. AMOs are easy to produce
and relatively cheap, and easy to administer locally (but
not systemically). Moreover, they possess low toxicity and
are highly speciﬁc. Most viral miRNAs identiﬁed so far
have little homology to each other and to known host cell
miRNAs (reviewed in [130]). This reduces the risk of oﬀ-
target eﬀects of anti-miRNA oligonucleotides and increases
the therapeutic potentials of miRNA silencing. The miRNA
silencing action of both LNA and antagomirs is sensitive to
single nucleotide exchanges. For antagomirs, it was shown
that this eﬀect depends on the position of the mismatch.
Nucleotide substitutions at the very 5’ end or in the centre
did not prevent downregulation of miR-122 [33]. These data
indicate that changes in the 3’ end of the antagomir may
abrogate its ability to destroy target miRNA and should be
taken into account when designing and testing antagomirs.
Another advantage of AMOs is that they probably can
be used against all serotypes of a speciﬁc virus. Although
not meticulously investigated, miRNA sequences between
diﬀerent viral strains seem to be conserved because of their
importance for the viral life-cycle (see e.g., KSHV-encoded
miRNAs; [80, 107, 108]). However, polymorphism in viral
miRNAs has also been observed (see next paragraph).
Although AMOs may provide an attractive novel antivi-
ral therapy, practical problems and other pitfalls may
hamper the use of them. For example, antagomirs directed
against miR-UL-112-1 could drive the virus towards acute
replication and disrupted the inhibition of MCIB expres-
sion, resulting in possible clearance of the virus by the
immune system. However, there is a potential risk of severe
pathological eﬀects caused by acutely replicating HCMV,
especially in immunocompromised patients [50]. Another
disadvantage of AMOs may be oﬀ-target eﬀects. As miRNA
do not require full complimentarity to bind their target
sequence, it can be imagined that an AMO not only binds
to its predicted miRNA but also to other miRNAs and even
mRNAs. In addition, ssRNA oligonucleotides may interact
with Toll-like receptors 7 and 8 thereby stimulating the
immune system. Similar side eﬀects have been reported for
siRNA (reviewed in [126]). Polymorphism in viral-encoded
miRNAs has been described in viral-infected cell lines and in
clinical samples. For instance, miR-K12-5 of diﬀerent KSHV
isolates contains mutations, which can aﬀect maturation and
biological activity of this miRNA [25, 100, 107]. Thus the
miRNA may not be expressed, in which case the AMO will
have no eﬀect or the AMO may not bind because of the
mutations in its target miRNA. Another problem facing the
use of AMOs in antiviral therapy is that the expression of
a speciﬁc gene may be regulated by several viral miRNAs.
For example, translation of the transcript of theBACHgene
is prevented by three KSHV viral miRNAS: miR-K12-11,
miRNA-K12-1, and miR-K12-6. Thus the eﬀectiveness of an
AMO against, for example, miR-12-11 can be compromised.
Indeed, treatment of latently infected KSHV virus with a
speciﬁc antagomir against miR-K12-12 alone only modestly
increased the amount of BACH protein [81]. A cocktail
of diﬀerent AMOs directed against distinct viral miRNA
m a yh e l pt oo v e r c o m et h i sp r o b l e m .S of a r ,s u c hs t u d i e s
are lacking, but a recent study successfully applied sponge
miRNA to silence HBV transcripts. An expression vector
encoding multiple miRNAs targeting HBV HBsAg mRNA
strongly reduced the expression of this protein [131].
AnotherchallengeistoimproveinvivodeliveryoftheAMOs
to viral infected cells and obtain long-lasting action of the
antagomirs. Aerosol delivery devices similar to the ones used
for delivery of asthma therapeutics could be used for respira-
tory viruses [15]. Other delivery strategies include intravenal
or systemic injection, viral vectors, and lipid- and polymer-
based vehicles [131–134]. Recently, sustained inhibition of
HCV replication in cell-culture was obtained when cell-
degradable multilayered polyelectrolyte ﬁlm (MPF) coated
with siRNA was delivered to infected cells. By this approach,
a single regime of MPF-mediated siRNA treatment was
suﬃcient to inhibit HCV replication for 12 days. Moreover,
MPF-mediated delivery of siRNA also protected uninfected
cells from HCV infection. Another advantage is the very
low toxicity of MPF [135]. These promising observations in
cell culture put MPF-based delivery of AMOs forward as an
eﬃcient antiviral tool. Another limitation of anti-miRNAs
is the site of application. Studies with antagomirs against
miR-16 in mice revealed that when injected into tail veins,
antagomirs were incapable of silencing miR-16, whereas
local injection into the mouse cortex eﬃciently induced
degradation of the target miRNA [33]. Another drawback
of the use of AMOs is that the chemical modiﬁcation can
exert antiproliferative or other oﬀ-target eﬀects such as been
demonstrated for the phosphorothioate backbone, which
can associate with cellular proteins [29].
Antisense oligonucleotides such as LNA and PMO have
proven to eﬃciently inhibit RNA and DNA virus replication
incellcultureandanimalmodels,withouttoxicityforthecell
or animal. However, these PMO were directed against viral
protein-encoding mRNA, and studies of PMO-mediated
silencing of viral miRNA have not been reported so far
(see e.g., [31, 136–138]). Future viral miRNA research is
faced with important challenges before AMOs may enter
the clinic. Our comprehension on the functions of viral
miRNAandtheinterplaybetweenviralinfectionandcellular
miRNA expression is just beginning to emerge. Studies
aimed at the identiﬁcation of viral miRNA and elucidation
of their functions should be pursued. Diﬃculties facing
computational-based prediction are false positives, but also
the shortcoming to detect genuine miRNAs. Moreover
conﬁrmation of expression of miRNA by, for example,
Northern blot may fail to monitor miRNA. Expression levels
of vmiRNA may be cell-speciﬁc, for example, EBV miR-
BHFR1-2 had considerably lower expression levels in Jijoye
cells than in B95-8 cells [7]. Dose- and time-dependent stud-
ies are required to determine the optimal therapeutic regime.
Such pharmacokinetics and pharmacodynamic studies are
largely lacking [133], but recent in studies in mice revealed
that a single cerebral or tail-vein injection of 240mg/kg body
mass anti-miR122 had a silencing eﬀect for at least 8 days
a n da sl o n ga s2 3d a y si nt h et i s s u e se x a m i n e d[ 32, 33]. In
another study, a ﬁve-week regime of two intraperitonal or
subcutaneous injection a week with diﬀerent concentrations
of anti-miR-122 clearly silenced miR-122 and no untoward14 Journal of Biomedicine and Biotechnology
eﬀects were observed [35]. Despite the obstacles facing
antiviral miRNA silencing as viral therapy, the coming years
will certainly see the daylight of intensiﬁed research and even
the initiation of clinical trials.
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